Mindstate Uses AI to Design “Next-Gen” Psychedelics Combined With 5-MeO-MiPT - Lucid News
Mindstate Design Labs has received approval for a Phase 1 clinical trial to investigate the use of its formulation of 5-MeO-MiPT which it hopes to combine with other drugs to target precise serotonin receptors and create future psychotropic therapies.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
